Difference between revisions of "Gene Editing Patent Application Trends 2024"
Jump to navigation
Jump to search
Wikipatents (talk | contribs) (Updating Gene Editing Patent Application Trends 2024) |
Wikipatents (talk | contribs) (Updating Gene Editing Patent Application Trends 2024) |
||
| Line 8: | Line 8: | ||
=== Top CPC Codes === | === Top CPC Codes === | ||
* [[:Category:CPC_C12N9/22|C12N9/22]] (No explanation available) | * [[:Category:CPC_C12N9/22|C12N9/22]] (No explanation available) | ||
| − | ** Count: | + | ** Count: 404 patents |
** Example: [[20240226152. SENOLYTIC CRISPR CAR T CELLS PRODUCED BY CRISPR-CAS9 GENOME EDITING (Wisconsin Alumni Research Foundation)]] | ** Example: [[20240226152. SENOLYTIC CRISPR CAR T CELLS PRODUCED BY CRISPR-CAS9 GENOME EDITING (Wisconsin Alumni Research Foundation)]] | ||
* [[:Category:CPC_C12N2310/20|C12N2310/20]] (No explanation available) | * [[:Category:CPC_C12N2310/20|C12N2310/20]] (No explanation available) | ||
| − | ** Count: | + | ** Count: 377 patents |
** Example: [[20240226246. NOVEL OMNI-50 CRISPR NUCLEASE (EmendoBio Inc.)]] | ** Example: [[20240226246. NOVEL OMNI-50 CRISPR NUCLEASE (EmendoBio Inc.)]] | ||
* [[:Category:CPC_C12N15/86|C12N15/86]] (No explanation available) | * [[:Category:CPC_C12N15/86|C12N15/86]] (No explanation available) | ||
| Line 17: | Line 17: | ||
** Example: [[20240226326. COMPOSITIONS AND METHODS FOR TREATING SENSORINEURAL HEARING LOSS USING OTOFERLIN DUAL VECTOR SYSTEMS (Decibel Therapeutics, Inc.)]] | ** Example: [[20240226326. COMPOSITIONS AND METHODS FOR TREATING SENSORINEURAL HEARING LOSS USING OTOFERLIN DUAL VECTOR SYSTEMS (Decibel Therapeutics, Inc.)]] | ||
* [[:Category:CPC_C12N15/11|C12N15/11]] (No explanation available) | * [[:Category:CPC_C12N15/11|C12N15/11]] (No explanation available) | ||
| − | ** Count: | + | ** Count: 205 patents |
** Example: [[20240226152. SENOLYTIC CRISPR CAR T CELLS PRODUCED BY CRISPR-CAS9 GENOME EDITING (Wisconsin Alumni Research Foundation)]] | ** Example: [[20240226152. SENOLYTIC CRISPR CAR T CELLS PRODUCED BY CRISPR-CAS9 GENOME EDITING (Wisconsin Alumni Research Foundation)]] | ||
* [[:Category:CPC_C12N2750/14143|C12N2750/14143]] (No explanation available) | * [[:Category:CPC_C12N2750/14143|C12N2750/14143]] (No explanation available) | ||
| Line 23: | Line 23: | ||
** Example: [[20240226332. GENE THERAPY FOR TREM2-ASSOCIATED DISEASES AND DISORDERS (Eli Lilly and Company)]] | ** Example: [[20240226332. GENE THERAPY FOR TREM2-ASSOCIATED DISEASES AND DISORDERS (Eli Lilly and Company)]] | ||
* [[:Category:CPC_C12N15/907|C12N15/907]] (No explanation available) | * [[:Category:CPC_C12N15/907|C12N15/907]] (No explanation available) | ||
| − | ** Count: | + | ** Count: 127 patents |
** Example: [[20240226246. NOVEL OMNI-50 CRISPR NUCLEASE (EmendoBio Inc.)]] | ** Example: [[20240226246. NOVEL OMNI-50 CRISPR NUCLEASE (EmendoBio Inc.)]] | ||
* [[:Category:CPC_A61K48/005|A61K48/005]] (No explanation available) | * [[:Category:CPC_A61K48/005|A61K48/005]] (No explanation available) | ||
| − | ** Count: | + | ** Count: 115 patents |
** Example: [[20240226326. COMPOSITIONS AND METHODS FOR TREATING SENSORINEURAL HEARING LOSS USING OTOFERLIN DUAL VECTOR SYSTEMS (Decibel Therapeutics, Inc.)]] | ** Example: [[20240226326. COMPOSITIONS AND METHODS FOR TREATING SENSORINEURAL HEARING LOSS USING OTOFERLIN DUAL VECTOR SYSTEMS (Decibel Therapeutics, Inc.)]] | ||
* [[:Category:CPC_C12N2800/80|C12N2800/80]] (No explanation available) | * [[:Category:CPC_C12N2800/80|C12N2800/80]] (No explanation available) | ||
| − | ** Count: | + | ** Count: 107 patents |
** Example: [[20240226246. NOVEL OMNI-50 CRISPR NUCLEASE (EmendoBio Inc.)]] | ** Example: [[20240226246. NOVEL OMNI-50 CRISPR NUCLEASE (EmendoBio Inc.)]] | ||
* [[:Category:CPC_C12N15/111|C12N15/111]] (No explanation available) | * [[:Category:CPC_C12N15/111|C12N15/111]] (No explanation available) | ||
| − | ** Count: | + | ** Count: 106 patents |
** Example: [[20240226334. CORRECTION OF DUCHENNE MUSCULAR DYSTROPHY MUTATIONS WITH ALL-IN-ONE ADENO-ASSOCIATED VIRUS-DELIVERED SINGLE-CUT CRISPR (The Board of Regents of The University of Texas System)]] | ** Example: [[20240226334. CORRECTION OF DUCHENNE MUSCULAR DYSTROPHY MUTATIONS WITH ALL-IN-ONE ADENO-ASSOCIATED VIRUS-DELIVERED SINGLE-CUT CRISPR (The Board of Regents of The University of Texas System)]] | ||
* [[:Category:CPC_C12N15/113|C12N15/113]] (No explanation available) | * [[:Category:CPC_C12N15/113|C12N15/113]] (No explanation available) | ||
| − | ** Count: | + | ** Count: 90 patents |
** Example: [[20240228546. METHODS AND PRODUCTS FOR GENETIC ENGINEERING (Institut National De La Sante Et De La Recherche Medicale (INSERM))]] | ** Example: [[20240228546. METHODS AND PRODUCTS FOR GENETIC ENGINEERING (Institut National De La Sante Et De La Recherche Medicale (INSERM))]] | ||
| Line 42: | Line 42: | ||
=== [[:Category:The Broad Institute, Inc.|The Broad Institute, Inc.]] === | === [[:Category:The Broad Institute, Inc.|The Broad Institute, Inc.]] === | ||
| − | * Number of Gene Editing patents: | + | * Number of Gene Editing patents: 25 |
* Top CPC codes: | * Top CPC codes: | ||
| − | ** [[:Category:CPC_C12N9/22|C12N9/22]] (No explanation available): | + | ** [[:Category:CPC_C12N9/22|C12N9/22]] (No explanation available): 19 patents |
| − | ** [[:Category:CPC_C12N2310/20|C12N2310/20]] (No explanation available): | + | ** [[:Category:CPC_C12N2310/20|C12N2310/20]] (No explanation available): 19 patents |
| − | ** [[:Category:CPC_C12N15/907|C12N15/907]] (No explanation available): | + | ** [[:Category:CPC_C12N15/907|C12N15/907]] (No explanation available): 12 patents |
* Recent patents: | * Recent patents: | ||
** [[20240327872. METHODS AND COMPOSITIONS FOR PRIME EDITING NUCLEOTIDE SEQUENCES (The Broad Institute, Inc.)]] (20241003) | ** [[20240327872. METHODS AND COMPOSITIONS FOR PRIME EDITING NUCLEOTIDE SEQUENCES (The Broad Institute, Inc.)]] (20241003) | ||
| Line 91: | Line 91: | ||
** [[20240175056. PRIME EDITING-BASED SIMULTANEOUS GENOMIC DELETION AND INSERTION (UNIVERSITY OF MASSACHUSETTS)]] (20240530) | ** [[20240175056. PRIME EDITING-BASED SIMULTANEOUS GENOMIC DELETION AND INSERTION (UNIVERSITY OF MASSACHUSETTS)]] (20240530) | ||
** [[20240167029. MODIFIED GUIDE RNAS FOR CRISPR GENOME EDITING (UNIVERSITY OF MASSACHUSETTS)]] (20240523) | ** [[20240167029. MODIFIED GUIDE RNAS FOR CRISPR GENOME EDITING (UNIVERSITY OF MASSACHUSETTS)]] (20240523) | ||
| + | === [[:Category:INBIOSE N.V.|INBIOSE N.V.]] === | ||
| + | * Number of Gene Editing patents: 11 | ||
| + | * Top CPC codes: | ||
| + | ** [[:Category:CPC_C12N9/1051|C12N9/1051]] (No explanation available): 7 patents | ||
| + | ** [[:Category:CPC_C12N9/1081|C12N9/1081]] (No explanation available): 5 patents | ||
| + | ** [[:Category:CPC_C12P19/12|C12P19/12]] (No explanation available): 5 patents | ||
| + | * Recent patents: | ||
| + | ** [[20240191270. FERMENTATIVE PRODUCTION (INBIOSE N.V.)]] (20240613) | ||
| + | ** [[20240084347. CELLULAR PRODUCTION OF GLYCOSYLATED PRODUCTS (INBIOSE N.V.)]] (20240314) | ||
| + | ** [[20240327888. LACTO-N-BIOSE CONVERTING FUCOSYLTRANSFERASES (INBIOSE N.V.)]] (20241003) | ||
=== [[:Category:THE BROAD INSTITUTE, INC.|THE BROAD INSTITUTE, INC.]] === | === [[:Category:THE BROAD INSTITUTE, INC.|THE BROAD INSTITUTE, INC.]] === | ||
* Number of Gene Editing patents: 10 | * Number of Gene Editing patents: 10 | ||
| Line 111: | Line 121: | ||
** [[20240011004. COMPOSITIONS COMPRISING A VARIANT CRISPR NUCLEASE POLYPEPTIDE AND USES THEREOF (Arbor Biotechnologies, Inc.)]] (20240111) | ** [[20240011004. COMPOSITIONS COMPRISING A VARIANT CRISPR NUCLEASE POLYPEPTIDE AND USES THEREOF (Arbor Biotechnologies, Inc.)]] (20240111) | ||
** [[20240409908. NOVEL CRISPR-ASSOCIATED TRANSPOSON SYSTEMS AND COMPONENTS (Arbor Biotechnologies, Inc.)]] (20241212) | ** [[20240409908. NOVEL CRISPR-ASSOCIATED TRANSPOSON SYSTEMS AND COMPONENTS (Arbor Biotechnologies, Inc.)]] (20241212) | ||
| + | === [[:Category:Regeneron Pharmaceuticals, Inc.|Regeneron Pharmaceuticals, Inc.]] === | ||
| + | * Number of Gene Editing patents: 10 | ||
| + | * Top CPC codes: | ||
| + | ** [[:Category:CPC_A01K2217/072|A01K2217/072]] (No explanation available): 6 patents | ||
| + | ** [[:Category:CPC_A01K2227/105|A01K2227/105]] (No explanation available): 6 patents | ||
| + | ** [[:Category:CPC_A01K67/0278|A01K67/0278]] (No explanation available): 5 patents | ||
| + | * Recent patents: | ||
| + | ** [[20240093316. CAS-READY MOUSE EMBRYONIC STEM CELLS AND MICE AND USES THEREOF (Regeneron Pharmaceuticals, Inc.)]] (20240321) | ||
| + | ** [[20240065239. MICE EXPRESSING HUMANIZED FC ALPHA RECEPTORS (Regeneron Pharmaceuticals, Inc.)]] (20240229) | ||
| + | ** [[20240084293. CRISPR/CAS SCREENING PLATFORM TO IDENTIFY GENETIC MODIFIERS OF TAU SEEDING OR AGGREGATION (Regeneron Pharmaceuticals, Inc.)]] (20240314) | ||
=== [[:Category:Massachusetts Institute of Technology|Massachusetts Institute of Technology]] === | === [[:Category:Massachusetts Institute of Technology|Massachusetts Institute of Technology]] === | ||
* Number of Gene Editing patents: 9 | * Number of Gene Editing patents: 9 | ||
| Line 121: | Line 141: | ||
** [[20240067961. SYSTEMS, METHODS, AND COMPOSITIONS FOR SITE-SPECIFIC GENETIC ENGINEERING USING PROGRAMMABLE ADDITION VIA SITE-SPECIFIC TARGETING ELEMENTS (PASTE) (Massachusetts Institute of Technology)]] (20240229) | ** [[20240067961. SYSTEMS, METHODS, AND COMPOSITIONS FOR SITE-SPECIFIC GENETIC ENGINEERING USING PROGRAMMABLE ADDITION VIA SITE-SPECIFIC TARGETING ELEMENTS (PASTE) (Massachusetts Institute of Technology)]] (20240229) | ||
** [[20240035031. TARGETED TRANS-SPLICING USING CRISPR/CAS13 (Massachusetts Institute of Technology)]] (20240201) | ** [[20240035031. TARGETED TRANS-SPLICING USING CRISPR/CAS13 (Massachusetts Institute of Technology)]] (20240201) | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
== New Companies in Gene Editing (Last Month) == | == New Companies in Gene Editing (Last Month) == | ||
| Line 200: | Line 200: | ||
** [[20240043828. T-DNA MEDIATED GENETIC MODIFICATION (THE BROAD INSTITUTE, INC.)]] (20240208) | ** [[20240043828. T-DNA MEDIATED GENETIC MODIFICATION (THE BROAD INSTITUTE, INC.)]] (20240208) | ||
** [[20240047011. METHODS FOR IDENTIFYING NOVEL GENE EDITING ELEMENTS (The Broad Institute, Inc.)]] (20240208) | ** [[20240047011. METHODS FOR IDENTIFYING NOVEL GENE EDITING ELEMENTS (The Broad Institute, Inc.)]] (20240208) | ||
| + | === [[:Category:David R. Liu|David R. Liu of Cambridge MA (US)]] === | ||
| + | * Number of Gene Editing patents: 11 | ||
| + | * Top companies: | ||
| + | ** [[:Category:The Broad Institute, Inc.|The Broad Institute, Inc.]]: 7 patents | ||
| + | ** [[:Category:President and Fellows of Harvard College|President and Fellows of Harvard College]]: 2 patents | ||
| + | ** [[:Category:President and Fellows of Harvard College|President and Fellows of Harvard College]]: 1 patents | ||
| + | * Recent patents: | ||
| + | ** [[20240344055. METHODS AND SYSTEMS FOR MODIFYING THE CRUMBS HOMOLOGUE-1 (CRB1) GENE (The Trustees of Columbia University in the City of New York)]] (20241017) | ||
| + | ** [[20240110166. EDITING OF CCR5 RECEPTOR GENE TO PROTECT AGAINST HIV INFECTION (President and Fellows of Harvard College)]] (20240404) | ||
| + | ** [[20240327872. METHODS AND COMPOSITIONS FOR PRIME EDITING NUCLEOTIDE SEQUENCES (The Broad Institute, Inc.)]] (20241003) | ||
| + | === [[:Category:Joeri Beauprez|Joeri Beauprez]] === | ||
| + | * Number of Gene Editing patents: 11 | ||
| + | * Top companies: | ||
| + | ** [[:Category:INBIOSE N.V.|INBIOSE N.V.]]: 11 patents | ||
| + | * Recent patents: | ||
| + | ** [[20240191270. FERMENTATIVE PRODUCTION (INBIOSE N.V.)]] (20240613) | ||
| + | ** [[20240084347. CELLULAR PRODUCTION OF GLYCOSYLATED PRODUCTS (INBIOSE N.V.)]] (20240314) | ||
| + | ** [[20240327888. LACTO-N-BIOSE CONVERTING FUCOSYLTRANSFERASES (INBIOSE N.V.)]] (20241003) | ||
=== [[:Category:Sean HIGGINS|Sean HIGGINS of Alameda CA (US)]] === | === [[:Category:Sean HIGGINS|Sean HIGGINS of Alameda CA (US)]] === | ||
* Number of Gene Editing patents: 9 | * Number of Gene Editing patents: 9 | ||
| Line 224: | Line 242: | ||
** [[20240026385. ENGINEERED CLASS 2 TYPE V CRISPR SYSTEMS (Scribe Therapeutics Inc.)]] (20240125) | ** [[20240026385. ENGINEERED CLASS 2 TYPE V CRISPR SYSTEMS (Scribe Therapeutics Inc.)]] (20240125) | ||
** [[20240026386. COMPOSITIONS AND METHODS FOR THE TARGETING OF BCL11A (Scribe Therapeutics Inc.)]] (20240125) | ** [[20240026386. COMPOSITIONS AND METHODS FOR THE TARGETING OF BCL11A (Scribe Therapeutics Inc.)]] (20240125) | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
=== [[:Category:Jonathan Gootenberg|Jonathan Gootenberg of Cambridge MA (US)]] === | === [[:Category:Jonathan Gootenberg|Jonathan Gootenberg of Cambridge MA (US)]] === | ||
* Number of Gene Editing patents: 8 | * Number of Gene Editing patents: 8 | ||
| Line 242: | Line 252: | ||
** [[20240191223. TYPE VI CRISPR ORTHOLOGS AND SYSTEMS (The Broad Institute, Inc.)]] (20240613) | ** [[20240191223. TYPE VI CRISPR ORTHOLOGS AND SYSTEMS (The Broad Institute, Inc.)]] (20240613) | ||
** [[20240327933. CORONAVIRUS RAPID DIAGNOSTICS (The Broad Institute, Inc.)]] (20241003) | ** [[20240327933. CORONAVIRUS RAPID DIAGNOSTICS (The Broad Institute, Inc.)]] (20241003) | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
=== [[:Category:Benjamin Julius RAUCH|Benjamin Julius RAUCH of San Francisco CA (US)]] === | === [[:Category:Benjamin Julius RAUCH|Benjamin Julius RAUCH of San Francisco CA (US)]] === | ||
* Number of Gene Editing patents: 7 | * Number of Gene Editing patents: 7 | ||
| Line 270: | Line 270: | ||
** [[20240093193. DEAD GUIDES FOR CRISPR TRANSCRIPTION FACTORS (The Broad Institute, Inc.)]] (20240321) | ** [[20240093193. DEAD GUIDES FOR CRISPR TRANSCRIPTION FACTORS (The Broad Institute, Inc.)]] (20240321) | ||
** [[20240067961. SYSTEMS, METHODS, AND COMPOSITIONS FOR SITE-SPECIFIC GENETIC ENGINEERING USING PROGRAMMABLE ADDITION VIA SITE-SPECIFIC TARGETING ELEMENTS (PASTE) (Massachusetts Institute of Technology)]] (20240229) | ** [[20240067961. SYSTEMS, METHODS, AND COMPOSITIONS FOR SITE-SPECIFIC GENETIC ENGINEERING USING PROGRAMMABLE ADDITION VIA SITE-SPECIFIC TARGETING ELEMENTS (PASTE) (Massachusetts Institute of Technology)]] (20240229) | ||
| + | === [[:Category:Annelies Vercauteren|Annelies Vercauteren]] === | ||
| + | * Number of Gene Editing patents: 7 | ||
| + | * Top companies: | ||
| + | ** [[:Category:INBIOSE N.V.|INBIOSE N.V.]]: 7 patents | ||
| + | * Recent patents: | ||
| + | ** [[20240209405. PRODUCTION OF A SIALYLATED OLIGOSACCHARIDE MIXTURE BY A CELL (INBIOSE N.V.)]] (20240627) | ||
| + | ** [[20240035004. VARIANT SUCROSE PERMEASE POLYPEPTIDES (INBIOSE N.V.)]] (20240201) | ||
| + | ** [[20240327888. LACTO-N-BIOSE CONVERTING FUCOSYLTRANSFERASES (INBIOSE N.V.)]] (20241003) | ||
| + | === [[:Category:Jesse Salk|Jesse Salk of Seattle WA (US)]] === | ||
| + | * Number of Gene Editing patents: 7 | ||
| + | * Top companies: | ||
| + | ** [[:Category:UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION|UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION]]: 7 patents | ||
| + | * Recent patents: | ||
| + | ** [[20240368692. METHODS OF LOWERING THE ERROR RATE OF MASSIVELY PARALLEL DNA SEQUENCING USING DUPLEX CONSENSUS SEQUENCING (UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION)]] (20241107) | ||
| + | ** [[20240035088. METHODS OF LOWERING THE ERROR RATE OF MASSIVELY PARALLEL DNA SEQUENCING USING DUPLEX CONSENSUS SEQUENCING (UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION)]] (20240201) | ||
| + | ** [[20240084385. METHODS OF LOWERING THE ERROR RATE OF MASSIVELY PARALLEL DNA SEQUENCING USING DUPLEX CONSENSUS SEQUENCING (UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION)]] (20240314) | ||
| + | === [[:Category:Lawrence A. Loeb|Lawrence A. Loeb of Bellevue WA (US)]] === | ||
| + | * Number of Gene Editing patents: 7 | ||
| + | * Top companies: | ||
| + | ** [[:Category:UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION|UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION]]: 7 patents | ||
| + | * Recent patents: | ||
| + | ** [[20240368692. METHODS OF LOWERING THE ERROR RATE OF MASSIVELY PARALLEL DNA SEQUENCING USING DUPLEX CONSENSUS SEQUENCING (UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION)]] (20241107) | ||
| + | ** [[20240035088. METHODS OF LOWERING THE ERROR RATE OF MASSIVELY PARALLEL DNA SEQUENCING USING DUPLEX CONSENSUS SEQUENCING (UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION)]] (20240201) | ||
| + | ** [[20240084385. METHODS OF LOWERING THE ERROR RATE OF MASSIVELY PARALLEL DNA SEQUENCING USING DUPLEX CONSENSUS SEQUENCING (UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION)]] (20240314) | ||
| + | === [[:Category:Michael Schmitt|Michael Schmitt of Seattle WA (US)]] === | ||
| + | * Number of Gene Editing patents: 7 | ||
| + | * Top companies: | ||
| + | ** [[:Category:UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION|UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION]]: 7 patents | ||
| + | * Recent patents: | ||
| + | ** [[20240368692. METHODS OF LOWERING THE ERROR RATE OF MASSIVELY PARALLEL DNA SEQUENCING USING DUPLEX CONSENSUS SEQUENCING (UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION)]] (20241107) | ||
| + | ** [[20240035088. METHODS OF LOWERING THE ERROR RATE OF MASSIVELY PARALLEL DNA SEQUENCING USING DUPLEX CONSENSUS SEQUENCING (UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION)]] (20240201) | ||
| + | ** [[20240084385. METHODS OF LOWERING THE ERROR RATE OF MASSIVELY PARALLEL DNA SEQUENCING USING DUPLEX CONSENSUS SEQUENCING (UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION)]] (20240314) | ||
=== [[:Category:Brett T. STAAHL|Brett T. STAAHL of Tiburon CA (US)]] === | === [[:Category:Brett T. STAAHL|Brett T. STAAHL of Tiburon CA (US)]] === | ||
* Number of Gene Editing patents: 6 | * Number of Gene Editing patents: 6 | ||
| Line 286: | Line 318: | ||
** [[20240218393. VECTORS ENCODING GENE EDITING SYSTEMS AND USES THEREOF (Mammoth Biosciences, Inc.)]] (20240704) | ** [[20240218393. VECTORS ENCODING GENE EDITING SYSTEMS AND USES THEREOF (Mammoth Biosciences, Inc.)]] (20240704) | ||
** [[20240327812. FUSION EFFECTOR PROTEINS AND USES THEREOF (Mammoth Biosciences, Inc.)]] (20241003) | ** [[20240327812. FUSION EFFECTOR PROTEINS AND USES THEREOF (Mammoth Biosciences, Inc.)]] (20241003) | ||
| + | === [[:Category:Kristof Vandewalle|Kristof Vandewalle]] === | ||
| + | * Number of Gene Editing patents: 6 | ||
| + | * Top companies: | ||
| + | ** [[:Category:INBIOSE N.V.|INBIOSE N.V.]]: 6 patents | ||
| + | * Recent patents: | ||
| + | ** [[20240209405. PRODUCTION OF A SIALYLATED OLIGOSACCHARIDE MIXTURE BY A CELL (INBIOSE N.V.)]] (20240627) | ||
| + | ** [[20240035004. VARIANT SUCROSE PERMEASE POLYPEPTIDES (INBIOSE N.V.)]] (20240201) | ||
| + | ** [[20240327888. LACTO-N-BIOSE CONVERTING FUCOSYLTRANSFERASES (INBIOSE N.V.)]] (20241003) | ||
=== [[:Category:Chenglong HAO|Chenglong HAO]] === | === [[:Category:Chenglong HAO|Chenglong HAO]] === | ||
* Number of Gene Editing patents: 6 | * Number of Gene Editing patents: 6 | ||
| Line 329: | Line 369: | ||
** [[20240060083. Gene therapy DNA vector based on gene therapy DNA vector VTvaf17 carrying the therapeutic gene selected from the group of SHH, CTNNB1, NOG, and WNT7A genes for increasing the expression level of these therapeutic genes, method of its production and use, Escherichia coli strain SCS110-AF/VTvaf17-SHH, or Escherichia coli strain SCS110-AF/VTvaf17-CTNNB1, or Escherichia coli strain SCS110-AF/VTvaf17-NOG, or Escherichia coli strain SCS110-AF/VTvaf17-WNT7A carrying the gene therapy DNA vector, method (CELL AND GENE THERAPY LTD)]] (20240222) | ** [[20240060083. Gene therapy DNA vector based on gene therapy DNA vector VTvaf17 carrying the therapeutic gene selected from the group of SHH, CTNNB1, NOG, and WNT7A genes for increasing the expression level of these therapeutic genes, method of its production and use, Escherichia coli strain SCS110-AF/VTvaf17-SHH, or Escherichia coli strain SCS110-AF/VTvaf17-CTNNB1, or Escherichia coli strain SCS110-AF/VTvaf17-NOG, or Escherichia coli strain SCS110-AF/VTvaf17-WNT7A carrying the gene therapy DNA vector, method (CELL AND GENE THERAPY LTD)]] (20240222) | ||
** [[20240325569. Gene therapy DNA vector based on gene therapy DNA vector VTvaf17 carrying the therapeutic gene selected from the group of BDNF, VEGFA, BFGF, NGF, GDNF, NT3, CNTF, and IGF1 genes for increasing the expression level of these therapeutic genes, method of its production and use, Escherichia coli strain SCS110-AF/VTvaf17-BDNF, or Escherichia coli strain SCS110-AF/VTvaf17-VEGFA, or Escherichia coli strain SCS110-AF/VTvaf17-BFGF, or Escherichia coli strain SCS110-AF/VTvaf17-NGF, or Escherichia coli str (CELL AND GENE THERAPY LTD)]] (20241003) | ** [[20240325569. Gene therapy DNA vector based on gene therapy DNA vector VTvaf17 carrying the therapeutic gene selected from the group of BDNF, VEGFA, BFGF, NGF, GDNF, NT3, CNTF, and IGF1 genes for increasing the expression level of these therapeutic genes, method of its production and use, Escherichia coli strain SCS110-AF/VTvaf17-BDNF, or Escherichia coli strain SCS110-AF/VTvaf17-VEGFA, or Escherichia coli strain SCS110-AF/VTvaf17-BFGF, or Escherichia coli strain SCS110-AF/VTvaf17-NGF, or Escherichia coli str (CELL AND GENE THERAPY LTD)]] (20241003) | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
=== [[:Category:Aaron DELOUGHERY|Aaron DELOUGHERY of San Francisco CA (US)]] === | === [[:Category:Aaron DELOUGHERY|Aaron DELOUGHERY of San Francisco CA (US)]] === | ||
* Number of Gene Editing patents: 5 | * Number of Gene Editing patents: 5 | ||
| Line 369: | Line 385: | ||
** [[20240131187. EFFECTOR PROTEINS, EFFECTOR PARTNERS, COMPOSITIONS, SYSTEMS AND METHODS OF USE THEREOF (Mammoth Biosciences, Inc.)]] (20240425) | ** [[20240131187. EFFECTOR PROTEINS, EFFECTOR PARTNERS, COMPOSITIONS, SYSTEMS AND METHODS OF USE THEREOF (Mammoth Biosciences, Inc.)]] (20240425) | ||
** [[20240191281. PROGRAMMABLE NUCLEASES AND METHODS OF USE (Mammoth Biosciences, Inc.)]] (20240613) | ** [[20240191281. PROGRAMMABLE NUCLEASES AND METHODS OF USE (Mammoth Biosciences, Inc.)]] (20240613) | ||
| + | === [[:Category:Andrew Vito Anzalone|Andrew Vito Anzalone of Cambridge MA (US)]] === | ||
| + | * Number of Gene Editing patents: 5 | ||
| + | * Top companies: | ||
| + | ** [[:Category:The Broad Institute, Inc.|The Broad Institute, Inc.]]: 5 patents | ||
| + | * Recent patents: | ||
| + | ** [[20240417719. METHODS AND COMPOSITIONS FOR EDITING A GENOME WITH PRIME EDITING AND A RECOMBINASE (The Broad Institute, Inc.)]] (20241219) | ||
| + | ** [[20240417753. METHODS AND COMPOSITIONS FOR EDITING NUCLEOTIDE SEQUENCES (The Broad Institute, Inc.)]] (20241219) | ||
| + | ** [[20240327872. METHODS AND COMPOSITIONS FOR PRIME EDITING NUCLEOTIDE SEQUENCES (The Broad Institute, Inc.)]] (20241003) | ||
=== [[:Category:Michael Coyle|Michael Coyle of Chapel Hill NC (US)]] === | === [[:Category:Michael Coyle|Michael Coyle of Chapel Hill NC (US)]] === | ||
* Number of Gene Editing patents: 5 | * Number of Gene Editing patents: 5 | ||
| Line 409: | Line 433: | ||
** [[20240209405. PRODUCTION OF A SIALYLATED OLIGOSACCHARIDE MIXTURE BY A CELL (INBIOSE N.V.)]] (20240627) | ** [[20240209405. PRODUCTION OF A SIALYLATED OLIGOSACCHARIDE MIXTURE BY A CELL (INBIOSE N.V.)]] (20240627) | ||
** [[20240191270. FERMENTATIVE PRODUCTION (INBIOSE N.V.)]] (20240613) | ** [[20240191270. FERMENTATIVE PRODUCTION (INBIOSE N.V.)]] (20240613) | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
=== [[:Category:Isabel COLIN|Isabel COLIN of Oakland CA (US)]] === | === [[:Category:Isabel COLIN|Isabel COLIN of Oakland CA (US)]] === | ||
* Number of Gene Editing patents: 5 | * Number of Gene Editing patents: 5 | ||
| Line 572: | Line 588: | ||
** [[20240084364. CRISPR ENZYMES AND SYSTEMS (The Broad Institute, Inc.)]] (20240314) | ** [[20240084364. CRISPR ENZYMES AND SYSTEMS (The Broad Institute, Inc.)]] (20240314) | ||
** [[20240327813. CRISPR ENZYMES, METHODS, SYSTEMS AND USES THEREOF (Beam Therapeutics Inc.)]] (20241003) | ** [[20240327813. CRISPR ENZYMES, METHODS, SYSTEMS AND USES THEREOF (Beam Therapeutics Inc.)]] (20241003) | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
=== [[:Category:Alim Ladha|Alim Ladha of Cambridge MA (US)]] === | === [[:Category:Alim Ladha|Alim Ladha of Cambridge MA (US)]] === | ||
* Number of Gene Editing patents: 4 | * Number of Gene Editing patents: 4 | ||
| Line 598: | Line 606: | ||
** [[20240067968. COMPOSITIONS, SYSTEMS, AND METHODS FOR REGULATION OF HEPATITIS B VIRUS THROUGH TARGETED GENE REPRESSION (Tune Therapeutics, Inc.)]] (20240229) | ** [[20240067968. COMPOSITIONS, SYSTEMS, AND METHODS FOR REGULATION OF HEPATITIS B VIRUS THROUGH TARGETED GENE REPRESSION (Tune Therapeutics, Inc.)]] (20240229) | ||
** [[20240067969. COMPOSITIONS, SYSTEMS, AND METHODS FOR REGULATION OF HEPATITIS B VIRUS THROUGH TARGETED GENE REPRESSION (Tune Therapeutics, Inc.)]] (20240229) | ** [[20240067969. COMPOSITIONS, SYSTEMS, AND METHODS FOR REGULATION OF HEPATITIS B VIRUS THROUGH TARGETED GENE REPRESSION (Tune Therapeutics, Inc.)]] (20240229) | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
== Top Collaborations in Gene Editing == | == Top Collaborations in Gene Editing == | ||
| Line 617: | Line 617: | ||
[[File:Top_20_Cities_for_Gene_Editing_Inventors.png|border|800px]] | [[File:Top_20_Cities_for_Gene_Editing_Inventors.png|border|800px]] | ||
| − | * Cambridge: | + | * Cambridge: 303 inventors |
* San Diego: 78 inventors | * San Diego: 78 inventors | ||
| + | * Boston: 65 inventors | ||
* San Francisco: 64 inventors | * San Francisco: 64 inventors | ||
| − | |||
* New York: 56 inventors | * New York: 56 inventors | ||
| − | * Seattle: | + | * Seattle: 53 inventors |
| + | * Zwijnaarde: 49 inventors | ||
* Durham: 46 inventors | * Durham: 46 inventors | ||
* Seoul: 46 inventors | * Seoul: 46 inventors | ||
| − | |||
* Shanghai: 39 inventors | * Shanghai: 39 inventors | ||
* London: 38 inventors | * London: 38 inventors | ||
| Line 635: | Line 635: | ||
* Beijing: 28 inventors | * Beijing: 28 inventors | ||
* Wuxi: 28 inventors | * Wuxi: 28 inventors | ||
| + | * Shenzhen: 27 inventors | ||
* Philadelphia: 27 inventors | * Philadelphia: 27 inventors | ||
| − | |||
[[Category:Gene Editing]] | [[Category:Gene Editing]] | ||
[[Category:Patent Application Trends by Technology in 2024]] | [[Category:Patent Application Trends by Technology in 2024]] | ||
Latest revision as of 16:07, 23 December 2024
Contents
- 1 Gene Editing Patent Application Filing Activity
- 2 Gene Editing patent applications in 2024
- 3 Top Technology Areas in Gene Editing
- 4 Top Companies in Gene Editing
- 4.1 The Broad Institute, Inc.
- 4.2 The Regents of the University of California
- 4.3 Mammoth Biosciences, Inc.
- 4.4 The Trustees of the University of Pennsylvania
- 4.5 UNIVERSITY OF MASSACHUSETTS
- 4.6 INBIOSE N.V.
- 4.7 THE BROAD INSTITUTE, INC.
- 4.8 Arbor Biotechnologies, Inc.
- 4.9 Regeneron Pharmaceuticals, Inc.
- 4.10 Massachusetts Institute of Technology
- 5 New Companies in Gene Editing (Last Month)
- 6 Emerging Technology Areas in Gene Editing
- 7 Top Companies in Emerging Gene Editing Technologies
- 8 Top Inventors in Gene Editing
- 8.1 Feng Zhang of Cambridge MA (US)
- 8.2 David R. Liu of Cambridge MA (US)
- 8.3 Joeri Beauprez
- 8.4 Sean HIGGINS of Alameda CA (US)
- 8.5 Sarah DENNY of San Francisco CA (US)
- 8.6 Benjamin OAKES of El Cerrito CA (US)
- 8.7 Jonathan Gootenberg of Cambridge MA (US)
- 8.8 Benjamin Julius RAUCH of San Francisco CA (US)
- 8.9 Omar Abudayyeh of Cambridge MA (US)
- 8.10 Annelies Vercauteren
- 8.11 Jesse Salk of Seattle WA (US)
- 8.12 Lawrence A. Loeb of Bellevue WA (US)
- 8.13 Michael Schmitt of Seattle WA (US)
- 8.14 Brett T. STAAHL of Tiburon CA (US)
- 8.15 Lucas Benjamin HARRINGTON of San Francisco CA (US)
- 8.16 Kristof Vandewalle
- 8.17 Chenglong HAO
- 8.18 Fengze TAN
- 8.19 Jian ZHU
- 8.20 James M. Wilson of Philadelphia PA (US)
- 8.21 Natalia SAVELIEVA
- 8.22 Aaron DELOUGHERY of San Francisco CA (US)
- 8.23 David PAEZ-ESPINO of Concord CA (US)
- 8.24 Andrew Vito Anzalone of Cambridge MA (US)
- 8.25 Michael Coyle of Chapel Hill NC (US)
- 8.26 Alexandra Briner Crawley of Cary NC (US)
- 8.27 Tedd D. Elich of Durham NC (US)
- 8.28 Pieter Coussement
- 8.29 Thomas Decoene
- 8.30 Isabel COLIN of Oakland CA (US)
- 8.31 Feng ZHANG of Cambridge MA (US)
- 8.32 Théophile OHLMANN
- 8.33 Philippe MANGEOT
- 8.34 Emiliano RICCI
- 8.35 Anurup Ganguli of San Diego CA (US)
- 8.36 Addison WRIGHT of El Cerrito CA (US)
- 8.37 Manuel MOHR of Berkeley CA (US)
- 8.38 Noah Michael Jakimo of Cambridge MA (US)
- 8.39 Kevin Flanigan of Columbus OH (US)
- 8.40 Manu Tamminen
- 8.41 Maroof ADIL of Davis CA (US)
- 8.42 Kamel KHALILI of Bala Cynwyd PA (US)
- 8.43 Christian Hinderer of Baltimore MD (US)
- 8.44 Guangping Gao of Worcester MA (US)
- 8.45 Christopher BROWN of Albany CA (US)
- 8.46 Angus SIDORE of Oakland CA (US)
- 8.47 Suraj MAKHIJA of San Francisco CA (US)
- 8.48 Bernd ZETSCHE of Cambridge MA (US)
- 8.49 Alim Ladha of Cambridge MA (US)
- 8.50 Kendra CONGDON of Durham NC (US)
- 9 Top Collaborations in Gene Editing
- 10 Top US States for Gene Editing Inventors
- 11 Top Cities for Gene Editing Inventors
Gene Editing Patent Application Filing Activity
Gene Editing patent applications in 2024
Top Technology Areas in Gene Editing
Top CPC Codes
- C12N9/22 (No explanation available)
- C12N2310/20 (No explanation available)
- Count: 377 patents
- Example: 20240226246. NOVEL OMNI-50 CRISPR NUCLEASE (EmendoBio Inc.)
- C12N15/86 (No explanation available)
- C12N15/11 (No explanation available)
- C12N2750/14143 (No explanation available)
- Count: 165 patents
- Example: 20240226332. GENE THERAPY FOR TREM2-ASSOCIATED DISEASES AND DISORDERS (Eli Lilly and Company)
- C12N15/907 (No explanation available)
- Count: 127 patents
- Example: 20240226246. NOVEL OMNI-50 CRISPR NUCLEASE (EmendoBio Inc.)
- A61K48/005 (No explanation available)
- C12N2800/80 (No explanation available)
- Count: 107 patents
- Example: 20240226246. NOVEL OMNI-50 CRISPR NUCLEASE (EmendoBio Inc.)
- C12N15/111 (No explanation available)
- C12N15/113 (No explanation available)
Top Companies in Gene Editing
The Broad Institute, Inc.
- Number of Gene Editing patents: 25
- Top CPC codes:
- C12N9/22 (No explanation available): 19 patents
- C12N2310/20 (No explanation available): 19 patents
- C12N15/907 (No explanation available): 12 patents
- Recent patents:
- 20240327872. METHODS AND COMPOSITIONS FOR PRIME EDITING NUCLEOTIDE SEQUENCES (The Broad Institute, Inc.) (20241003)
- 20240327933. CORONAVIRUS RAPID DIAGNOSTICS (The Broad Institute, Inc.) (20241003)
- 20240047011. METHODS FOR IDENTIFYING NOVEL GENE EDITING ELEMENTS (The Broad Institute, Inc.) (20240208)
The Regents of the University of California
- Number of Gene Editing patents: 19
- Top CPC codes:
- C12N9/22 (No explanation available): 10 patents
- C12N2310/20 (No explanation available): 10 patents
- C12N15/11 (No explanation available): 7 patents
- Recent patents:
- 20240216541. GENE THERAPY FOR ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY (The Regents of the University of California) (20240704)
- 20240023528. ONE-LOCUS INDUCIBLE PRECISION GUIDED STERILE INSECT TECHNIQUE OR TEMPERATURE-INDUCIBLE PRECISION GUIDED STERILE INSECT TECHNIQUE (The Regents of the University of California) (20240125)
- 20240026321. CRISPR-CAS EFFECTOR POLYPEPTIDES AND METHODS OF USE THEREOF (The Regents of the University of California) (20240125)
Mammoth Biosciences, Inc.
- Number of Gene Editing patents: 11
- Top CPC codes:
- C12N9/22 (No explanation available): 8 patents
- C12N15/11 (No explanation available): 6 patents
- C12N2310/20 (No explanation available): 6 patents
- Recent patents:
- 20240084275. COMPOSITIONS AND METHODS OF USING PROGRAMMABLE NUCLEASES FOR INDUCING CELL DEATH (Mammoth Biosciences, Inc.) (20240314)
- 20240218393. VECTORS ENCODING GENE EDITING SYSTEMS AND USES THEREOF (Mammoth Biosciences, Inc.) (20240704)
- 20240327812. FUSION EFFECTOR PROTEINS AND USES THEREOF (Mammoth Biosciences, Inc.) (20241003)
The Trustees of the University of Pennsylvania
- Number of Gene Editing patents: 11
- Top CPC codes:
- C12N15/86 (No explanation available): 7 patents
- A61K48/005 (No explanation available): 5 patents
- C12N2750/14143 (No explanation available): 5 patents
- Recent patents:
- 20240218394. GENE THERAPY FOR OCULAR DISORDERS (The Trustees of the University of Pennsylvania) (20240704)
- 20240316107. Compositions and Methods for Gene Editing in T Cells Using CRISPR/Cpf1 (The Trustees of the University of Pennsylvania) (20240926)
- 20240024510. GENE THERAPY FOR TREATING MUCOPOLYSACCHARIDOSIS TYPE I (The Trustees of the University of Pennsylvania) (20240125)
UNIVERSITY OF MASSACHUSETTS
- Number of Gene Editing patents: 11
- Top CPC codes:
- C12N9/22 (No explanation available): 8 patents
- C12N2310/20 (No explanation available): 7 patents
- C12N15/907 (No explanation available): 5 patents
- Recent patents:
- 20240018479. METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCLE DISEASE WITH IPSC-INDUCED HUMAN SKELETAL MUSCLE STEM CELLS (UNIVERSITY OF MASSACHUSETTS) (20240118)
- 20240175056. PRIME EDITING-BASED SIMULTANEOUS GENOMIC DELETION AND INSERTION (UNIVERSITY OF MASSACHUSETTS) (20240530)
- 20240167029. MODIFIED GUIDE RNAS FOR CRISPR GENOME EDITING (UNIVERSITY OF MASSACHUSETTS) (20240523)
INBIOSE N.V.
- Number of Gene Editing patents: 11
- Top CPC codes:
- C12N9/1051 (No explanation available): 7 patents
- C12N9/1081 (No explanation available): 5 patents
- C12P19/12 (No explanation available): 5 patents
- Recent patents:
THE BROAD INSTITUTE, INC.
- Number of Gene Editing patents: 10
- Top CPC codes:
- C12N2310/20 (No explanation available): 9 patents
- C12N9/22 (No explanation available): 8 patents
- C12N15/102 (No explanation available): 5 patents
- Recent patents:
Arbor Biotechnologies, Inc.
- Number of Gene Editing patents: 10
- Top CPC codes:
- C12N9/22 (No explanation available): 10 patents
- C12N2310/20 (No explanation available): 10 patents
- C12N15/907 (No explanation available): 5 patents
- Recent patents:
- 20240261435. GENE EDITING SYSTEMS COMPRISING AN RNA GUIDE TARGETING TRANSTHYRETIN (TTR) AND USES THEREOF (Arbor Biotechnologies, Inc.) (20240808)
- 20240011004. COMPOSITIONS COMPRISING A VARIANT CRISPR NUCLEASE POLYPEPTIDE AND USES THEREOF (Arbor Biotechnologies, Inc.) (20240111)
- 20240409908. NOVEL CRISPR-ASSOCIATED TRANSPOSON SYSTEMS AND COMPONENTS (Arbor Biotechnologies, Inc.) (20241212)
Regeneron Pharmaceuticals, Inc.
- Number of Gene Editing patents: 10
- Top CPC codes:
- A01K2217/072 (No explanation available): 6 patents
- A01K2227/105 (No explanation available): 6 patents
- A01K67/0278 (No explanation available): 5 patents
- Recent patents:
- 20240093316. CAS-READY MOUSE EMBRYONIC STEM CELLS AND MICE AND USES THEREOF (Regeneron Pharmaceuticals, Inc.) (20240321)
- 20240065239. MICE EXPRESSING HUMANIZED FC ALPHA RECEPTORS (Regeneron Pharmaceuticals, Inc.) (20240229)
- 20240084293. CRISPR/CAS SCREENING PLATFORM TO IDENTIFY GENETIC MODIFIERS OF TAU SEEDING OR AGGREGATION (Regeneron Pharmaceuticals, Inc.) (20240314)
Massachusetts Institute of Technology
- Number of Gene Editing patents: 9
- Top CPC codes:
- C12N9/22 (No explanation available): 7 patents
- C12N2310/20 (No explanation available): 7 patents
- C12N15/111 (No explanation available): 5 patents
- Recent patents:
- 20240067957. AUTOCATALYTIC BASE EDITING FOR RNA-RESPONSIVE TRANSLATIONAL CONTROL (Massachusetts Institute of Technology) (20240229)
- 20240067961. SYSTEMS, METHODS, AND COMPOSITIONS FOR SITE-SPECIFIC GENETIC ENGINEERING USING PROGRAMMABLE ADDITION VIA SITE-SPECIFIC TARGETING ELEMENTS (PASTE) (Massachusetts Institute of Technology) (20240229)
- 20240035031. TARGETED TRANS-SPLICING USING CRISPR/CAS13 (Massachusetts Institute of Technology) (20240201)
New Companies in Gene Editing (Last Month)
No new companies detected in the last month.
Emerging Technology Areas in Gene Editing
- G06N3/088 (No explanation available)
- Count: 1 patents
- Example: 20240047011. METHODS FOR IDENTIFYING NOVEL GENE EDITING ELEMENTS (The Broad Institute, Inc.)
- G06F18/2413 (No explanation available)
- Count: 1 patents
- Example: 20240047011. METHODS FOR IDENTIFYING NOVEL GENE EDITING ELEMENTS (The Broad Institute, Inc.)
- G06F18/295 (No explanation available)
- Count: 1 patents
- Example: 20240047011. METHODS FOR IDENTIFYING NOVEL GENE EDITING ELEMENTS (The Broad Institute, Inc.)
- G06F18/231 (No explanation available)
- Count: 1 patents
- Example: 20240047011. METHODS FOR IDENTIFYING NOVEL GENE EDITING ELEMENTS (The Broad Institute, Inc.)
- G16B40/30 (No explanation available)
- Count: 1 patents
- Example: 20240047011. METHODS FOR IDENTIFYING NOVEL GENE EDITING ELEMENTS (The Broad Institute, Inc.)
- G09B19/00 (No explanation available)
- Count: 1 patents
- Example: 20240046217. TALENT MOBILITY PLATFORM (ADP, Inc.)
- A61L2430/02 (No explanation available)
- Count: 1 patents
- Example: 20240043818. Engineered Cells for Increased Collagen Production (Northeastern University)
- A61L2430/16 (No explanation available)
- Count: 1 patents
- Example: 20240043818. Engineered Cells for Increased Collagen Production (Northeastern University)
- A61L26/0033 (No explanation available)
- Count: 1 patents
- Example: 20240043818. Engineered Cells for Increased Collagen Production (Northeastern University)
- A61L27/24 (No explanation available)
- Count: 1 patents
- Example: 20240043818. Engineered Cells for Increased Collagen Production (Northeastern University)
Top Companies in Emerging Gene Editing Technologies
- The Broad Institute, Inc.: 5 patents
- Northeastern University: 4 patents
- ADP, Inc.: 1 patents
Top Inventors in Gene Editing
Feng Zhang of Cambridge MA (US)
- Number of Gene Editing patents: 21
- Top companies:
- The Broad Institute, Inc.: 12 patents
- THE BROAD INSTITUTE, INC.: 9 patents
- Recent patents:
David R. Liu of Cambridge MA (US)
- Number of Gene Editing patents: 11
- Top companies:
- The Broad Institute, Inc.: 7 patents
- President and Fellows of Harvard College: 2 patents
- President and Fellows of Harvard College: 1 patents
- Recent patents:
- 20240344055. METHODS AND SYSTEMS FOR MODIFYING THE CRUMBS HOMOLOGUE-1 (CRB1) GENE (The Trustees of Columbia University in the City of New York) (20241017)
- 20240110166. EDITING OF CCR5 RECEPTOR GENE TO PROTECT AGAINST HIV INFECTION (President and Fellows of Harvard College) (20240404)
- 20240327872. METHODS AND COMPOSITIONS FOR PRIME EDITING NUCLEOTIDE SEQUENCES (The Broad Institute, Inc.) (20241003)
Joeri Beauprez
- Number of Gene Editing patents: 11
- Top companies:
- INBIOSE N.V.: 11 patents
- Recent patents:
Sean HIGGINS of Alameda CA (US)
- Number of Gene Editing patents: 9
- Top companies:
- Scribe Therapeutics Inc.: 9 patents
- Recent patents:
Sarah DENNY of San Francisco CA (US)
- Number of Gene Editing patents: 9
- Top companies:
- Scribe Therapeutics Inc.: 9 patents
- Recent patents:
Benjamin OAKES of El Cerrito CA (US)
- Number of Gene Editing patents: 9
- Top companies:
- Scribe Therapeutics Inc.: 9 patents
- Recent patents:
Jonathan Gootenberg of Cambridge MA (US)
- Number of Gene Editing patents: 8
- Top companies:
- Massachusetts Institute of Technology: 4 patents
- The Broad Institute, Inc.: 2 patents
- MASSACHUSETTS INSTITUTE OF TECHNOLOGY: 1 patents
- Recent patents:
- 20240067961. SYSTEMS, METHODS, AND COMPOSITIONS FOR SITE-SPECIFIC GENETIC ENGINEERING USING PROGRAMMABLE ADDITION VIA SITE-SPECIFIC TARGETING ELEMENTS (PASTE) (Massachusetts Institute of Technology) (20240229)
- 20240191223. TYPE VI CRISPR ORTHOLOGS AND SYSTEMS (The Broad Institute, Inc.) (20240613)
- 20240327933. CORONAVIRUS RAPID DIAGNOSTICS (The Broad Institute, Inc.) (20241003)
Benjamin Julius RAUCH of San Francisco CA (US)
- Number of Gene Editing patents: 7
- Top companies:
- Mammoth Biosciences, Inc.: 7 patents
- Recent patents:
Omar Abudayyeh of Cambridge MA (US)
- Number of Gene Editing patents: 7
- Top companies:
- Massachusetts Institute of Technology: 4 patents
- MASSACHUSETTS INSTITUTE OF TECHNOLOGY: 1 patents
- THE BROAD INSTITUTE, INC.: 1 patents
- Recent patents:
- 20240132883. RNA-TRIGGERED PROTEIN CLEAVAGE AND APPLICATIONS BY THE CRISPR CAS7-11-CSX29 COMPLEX (Massachusetts Institute of Technology) (20240425)
- 20240093193. DEAD GUIDES FOR CRISPR TRANSCRIPTION FACTORS (The Broad Institute, Inc.) (20240321)
- 20240067961. SYSTEMS, METHODS, AND COMPOSITIONS FOR SITE-SPECIFIC GENETIC ENGINEERING USING PROGRAMMABLE ADDITION VIA SITE-SPECIFIC TARGETING ELEMENTS (PASTE) (Massachusetts Institute of Technology) (20240229)
Annelies Vercauteren
- Number of Gene Editing patents: 7
- Top companies:
- INBIOSE N.V.: 7 patents
- Recent patents:
Jesse Salk of Seattle WA (US)
- Number of Gene Editing patents: 7
- Top companies:
- Recent patents:
- 20240368692. METHODS OF LOWERING THE ERROR RATE OF MASSIVELY PARALLEL DNA SEQUENCING USING DUPLEX CONSENSUS SEQUENCING (UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION) (20241107)
- 20240035088. METHODS OF LOWERING THE ERROR RATE OF MASSIVELY PARALLEL DNA SEQUENCING USING DUPLEX CONSENSUS SEQUENCING (UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION) (20240201)
- 20240084385. METHODS OF LOWERING THE ERROR RATE OF MASSIVELY PARALLEL DNA SEQUENCING USING DUPLEX CONSENSUS SEQUENCING (UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION) (20240314)
Lawrence A. Loeb of Bellevue WA (US)
- Number of Gene Editing patents: 7
- Top companies:
- Recent patents:
- 20240368692. METHODS OF LOWERING THE ERROR RATE OF MASSIVELY PARALLEL DNA SEQUENCING USING DUPLEX CONSENSUS SEQUENCING (UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION) (20241107)
- 20240035088. METHODS OF LOWERING THE ERROR RATE OF MASSIVELY PARALLEL DNA SEQUENCING USING DUPLEX CONSENSUS SEQUENCING (UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION) (20240201)
- 20240084385. METHODS OF LOWERING THE ERROR RATE OF MASSIVELY PARALLEL DNA SEQUENCING USING DUPLEX CONSENSUS SEQUENCING (UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION) (20240314)
Michael Schmitt of Seattle WA (US)
- Number of Gene Editing patents: 7
- Top companies:
- Recent patents:
- 20240368692. METHODS OF LOWERING THE ERROR RATE OF MASSIVELY PARALLEL DNA SEQUENCING USING DUPLEX CONSENSUS SEQUENCING (UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION) (20241107)
- 20240035088. METHODS OF LOWERING THE ERROR RATE OF MASSIVELY PARALLEL DNA SEQUENCING USING DUPLEX CONSENSUS SEQUENCING (UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION) (20240201)
- 20240084385. METHODS OF LOWERING THE ERROR RATE OF MASSIVELY PARALLEL DNA SEQUENCING USING DUPLEX CONSENSUS SEQUENCING (UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION) (20240314)
Brett T. STAAHL of Tiburon CA (US)
- Number of Gene Editing patents: 6
- Top companies:
- Scribe Therapeutics Inc.: 6 patents
- Recent patents:
Lucas Benjamin HARRINGTON of San Francisco CA (US)
- Number of Gene Editing patents: 6
- Top companies:
- Mammoth Biosciences, Inc.: 6 patents
- Recent patents:
- 20240084275. COMPOSITIONS AND METHODS OF USING PROGRAMMABLE NUCLEASES FOR INDUCING CELL DEATH (Mammoth Biosciences, Inc.) (20240314)
- 20240218393. VECTORS ENCODING GENE EDITING SYSTEMS AND USES THEREOF (Mammoth Biosciences, Inc.) (20240704)
- 20240327812. FUSION EFFECTOR PROTEINS AND USES THEREOF (Mammoth Biosciences, Inc.) (20241003)
Kristof Vandewalle
- Number of Gene Editing patents: 6
- Top companies:
- INBIOSE N.V.: 6 patents
- Recent patents:
Chenglong HAO
- Number of Gene Editing patents: 6
- Top companies:
- SHENZHEN METALENX TECHNOLOGY CO.,LTD: 5 patents
- SHENZHEN METALENX TECHNOLOGY CO., LTD: 1 patents
- Recent patents:
- 20240345463. POINT CLOUD PROJECTION SYSTEM (SHENZHEN METALENX TECHNOLOGY CO.,LTD) (20241017)
- 20240315540. ENDOSCOPIC PROBE, ENDOSCOPE AND METHOD OF SCANNING CONTROL (SHENZHEN METALENX TECHNOLOGY CO.,LTD) (20240926)
- 20240319016. METALENS ARRAY AND WAVEFRONT SENSOR SYSTEM (SHENZHEN METALENX TECHNOLOGY CO.,LTD) (20240926)
Fengze TAN
- Number of Gene Editing patents: 6
- Top companies:
- SHENZHEN METALENX TECHNOLOGY CO.,LTD: 5 patents
- SHENZHEN METALENX TECHNOLOGY CO., LTD: 1 patents
- Recent patents:
- 20240345463. POINT CLOUD PROJECTION SYSTEM (SHENZHEN METALENX TECHNOLOGY CO.,LTD) (20241017)
- 20240315540. ENDOSCOPIC PROBE, ENDOSCOPE AND METHOD OF SCANNING CONTROL (SHENZHEN METALENX TECHNOLOGY CO.,LTD) (20240926)
- 20240319016. METALENS ARRAY AND WAVEFRONT SENSOR SYSTEM (SHENZHEN METALENX TECHNOLOGY CO.,LTD) (20240926)
Jian ZHU
- Number of Gene Editing patents: 6
- Top companies:
- SHENZHEN METALENX TECHNOLOGY CO.,LTD: 5 patents
- SHENZHEN METALENX TECHNOLOGY CO., LTD: 1 patents
- Recent patents:
- 20240345463. POINT CLOUD PROJECTION SYSTEM (SHENZHEN METALENX TECHNOLOGY CO.,LTD) (20241017)
- 20240315540. ENDOSCOPIC PROBE, ENDOSCOPE AND METHOD OF SCANNING CONTROL (SHENZHEN METALENX TECHNOLOGY CO.,LTD) (20240926)
- 20240319016. METALENS ARRAY AND WAVEFRONT SENSOR SYSTEM (SHENZHEN METALENX TECHNOLOGY CO.,LTD) (20240926)
James M. Wilson of Philadelphia PA (US)
- Number of Gene Editing patents: 6
- Top companies:
- Recent patents:
- 20240197916. COMPOSITIONS AND METHODS FOR IN VIVO NUCLEASE-MEDIATED GENE TARGETING FOR THE TREATMENT OF GENETIC DISORDERS (The Trustees of the University of Pennsylvania) (20240620)
- 20240016903. GENE THERAPY FOR TREATING MUCOPOLYSACCHARIDOSIS TYPE II (The Trustees of the University of Pennsylvania) (20240118)
- 20240024510. GENE THERAPY FOR TREATING MUCOPOLYSACCHARIDOSIS TYPE I (The Trustees of the University of Pennsylvania) (20240125)
Natalia SAVELIEVA
- Number of Gene Editing patents: 6
- Top companies:
- CELL AND GENE THERAPY LTD: 6 patents
- Recent patents:
- [[20240366787. Gene therapy DNA vector based on gene therapy DNA vector VTvaf17 carrying the therapeutic gene selected from the group of NOS2, NOS3, VIP, KCNMA1, and CGRP genes for increasing the expression level of these therapeutic genes, method of its production and use, Escherichia coli strain SCS110-AF/VTvaf17-NOS2, or Escherichia coli strain SCS110-AF/VTvaf17-NOS3, or Escherichia coli strain SCS110-AF/VTvaf17-VIP, or Escherichia coli strain SCS110-AF/VTvaf17-KCNMA1, or Escherichia coli strain SCS110-AF/V (CELL AND GENE THERAPY LTD)]] (20241107)
- [[20240060083. Gene therapy DNA vector based on gene therapy DNA vector VTvaf17 carrying the therapeutic gene selected from the group of SHH, CTNNB1, NOG, and WNT7A genes for increasing the expression level of these therapeutic genes, method of its production and use, Escherichia coli strain SCS110-AF/VTvaf17-SHH, or Escherichia coli strain SCS110-AF/VTvaf17-CTNNB1, or Escherichia coli strain SCS110-AF/VTvaf17-NOG, or Escherichia coli strain SCS110-AF/VTvaf17-WNT7A carrying the gene therapy DNA vector, method (CELL AND GENE THERAPY LTD)]] (20240222)
- [[20240325569. Gene therapy DNA vector based on gene therapy DNA vector VTvaf17 carrying the therapeutic gene selected from the group of BDNF, VEGFA, BFGF, NGF, GDNF, NT3, CNTF, and IGF1 genes for increasing the expression level of these therapeutic genes, method of its production and use, Escherichia coli strain SCS110-AF/VTvaf17-BDNF, or Escherichia coli strain SCS110-AF/VTvaf17-VEGFA, or Escherichia coli strain SCS110-AF/VTvaf17-BFGF, or Escherichia coli strain SCS110-AF/VTvaf17-NGF, or Escherichia coli str (CELL AND GENE THERAPY LTD)]] (20241003)
Aaron DELOUGHERY of San Francisco CA (US)
- Number of Gene Editing patents: 5
- Top companies:
- Mammoth Biosciences, Inc.: 5 patents
- Recent patents:
David PAEZ-ESPINO of Concord CA (US)
- Number of Gene Editing patents: 5
- Top companies:
- Mammoth Biosciences, Inc.: 5 patents
- Recent patents:
- 20240271113. EFFECTOR PROTEINS AND METHODS OF USE (Mammoth Biosciences, Inc.) (20240815)
- 20240131187. EFFECTOR PROTEINS, EFFECTOR PARTNERS, COMPOSITIONS, SYSTEMS AND METHODS OF USE THEREOF (Mammoth Biosciences, Inc.) (20240425)
- 20240191281. PROGRAMMABLE NUCLEASES AND METHODS OF USE (Mammoth Biosciences, Inc.) (20240613)
Andrew Vito Anzalone of Cambridge MA (US)
- Number of Gene Editing patents: 5
- Top companies:
- The Broad Institute, Inc.: 5 patents
- Recent patents:
- 20240417719. METHODS AND COMPOSITIONS FOR EDITING A GENOME WITH PRIME EDITING AND A RECOMBINASE (The Broad Institute, Inc.) (20241219)
- 20240417753. METHODS AND COMPOSITIONS FOR EDITING NUCLEOTIDE SEQUENCES (The Broad Institute, Inc.) (20241219)
- 20240327872. METHODS AND COMPOSITIONS FOR PRIME EDITING NUCLEOTIDE SEQUENCES (The Broad Institute, Inc.) (20241003)
Michael Coyle of Chapel Hill NC (US)
- Number of Gene Editing patents: 5
- Top companies:
- LifeEDIT Therapeutics, Inc.: 5 patents
- Recent patents:
- 20240376456. RNA-GUIDED NUCLEASES AND ACTIVE FRAGMENTS AND VARIANTS THEREOF AND METHODS OF USE (LifeEDIT Therapeutics, Inc.) (20241114)
- 20240401084. RNA-GUIDED NUCLEASES AND ACTIVE FRAGMENTS AND VARIANTS THEREOF AND METHODS OF USE (LifeEDIT Therapeutics, Inc.) (20241205)
- 20240026384. RNA-GUIDED NUCLEASES AND ACTIVE FRAGMENTS AND VARIANTS THEREOF AND METHODS OF USE (LifeEDIT Therapeutics, Inc.) (20240125)
Alexandra Briner Crawley of Cary NC (US)
- Number of Gene Editing patents: 5
- Top companies:
- LifeEDIT Therapeutics, Inc.: 5 patents
- Recent patents:
- 20240376456. RNA-GUIDED NUCLEASES AND ACTIVE FRAGMENTS AND VARIANTS THEREOF AND METHODS OF USE (LifeEDIT Therapeutics, Inc.) (20241114)
- 20240401084. RNA-GUIDED NUCLEASES AND ACTIVE FRAGMENTS AND VARIANTS THEREOF AND METHODS OF USE (LifeEDIT Therapeutics, Inc.) (20241205)
- 20240026384. RNA-GUIDED NUCLEASES AND ACTIVE FRAGMENTS AND VARIANTS THEREOF AND METHODS OF USE (LifeEDIT Therapeutics, Inc.) (20240125)
Tedd D. Elich of Durham NC (US)
- Number of Gene Editing patents: 5
- Top companies:
- LifeEDIT Therapeutics, Inc.: 5 patents
- Recent patents:
- 20240376456. RNA-GUIDED NUCLEASES AND ACTIVE FRAGMENTS AND VARIANTS THEREOF AND METHODS OF USE (LifeEDIT Therapeutics, Inc.) (20241114)
- 20240401084. RNA-GUIDED NUCLEASES AND ACTIVE FRAGMENTS AND VARIANTS THEREOF AND METHODS OF USE (LifeEDIT Therapeutics, Inc.) (20241205)
- 20240026384. RNA-GUIDED NUCLEASES AND ACTIVE FRAGMENTS AND VARIANTS THEREOF AND METHODS OF USE (LifeEDIT Therapeutics, Inc.) (20240125)
Pieter Coussement
- Number of Gene Editing patents: 5
- Top companies:
- INBIOSE N.V.: 5 patents
- Recent patents:
Thomas Decoene
- Number of Gene Editing patents: 5
- Top companies:
- INBIOSE N.V.: 5 patents
- Recent patents:
Isabel COLIN of Oakland CA (US)
- Number of Gene Editing patents: 5
- Top companies:
- Scribe Therapeutics Inc.: 5 patents
- Recent patents:
Feng ZHANG of Cambridge MA (US)
- Number of Gene Editing patents: 5
- Top companies:
- The Broad Institute, Inc.: 5 patents
- Recent patents:
- 20240035007. SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION WITH OPTIMIZED FUNCTIONAL CRISPR-CAS SYSTEMS (The Broad Institute, Inc.) (20240201)
- 20240035048. DELIVERY, ENGINEERING AND OPTIMIZATION OF SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION AND THERAPEUTIC APPLICATIONS (The Broad Institute, Inc.) (20240201)
- 20240084364. CRISPR ENZYMES AND SYSTEMS (The Broad Institute, Inc.) (20240314)
Théophile OHLMANN
- Number of Gene Editing patents: 4
- Top companies:
- Recent patents:
- 20240409588. METHODS AND PRODUCTS FOR GENETIC ENGINEERING (Institut National De La Sante Et De La Recherche Medicale (INSERM)) (20241212)
- 20240132547. METHODS AND PRODUCTS FOR GENETIC ENGINEERING (Institut National De La Sante Et De La Recherche Medicale (INSERM)) (20240425)
- 20240109940. METHODS AND PRODUCTS FOR GENETIC ENGINEERING (Institut National De La Sante Et De La Recherche Medicale (INSERM)) (20240404)
Philippe MANGEOT
- Number of Gene Editing patents: 4
- Top companies:
- Recent patents:
- 20240409588. METHODS AND PRODUCTS FOR GENETIC ENGINEERING (Institut National De La Sante Et De La Recherche Medicale (INSERM)) (20241212)
- 20240132547. METHODS AND PRODUCTS FOR GENETIC ENGINEERING (Institut National De La Sante Et De La Recherche Medicale (INSERM)) (20240425)
- 20240109940. METHODS AND PRODUCTS FOR GENETIC ENGINEERING (Institut National De La Sante Et De La Recherche Medicale (INSERM)) (20240404)
Emiliano RICCI
- Number of Gene Editing patents: 4
- Top companies:
- Recent patents:
- 20240409588. METHODS AND PRODUCTS FOR GENETIC ENGINEERING (Institut National De La Sante Et De La Recherche Medicale (INSERM)) (20241212)
- 20240132547. METHODS AND PRODUCTS FOR GENETIC ENGINEERING (Institut National De La Sante Et De La Recherche Medicale (INSERM)) (20240425)
- 20240109940. METHODS AND PRODUCTS FOR GENETIC ENGINEERING (Institut National De La Sante Et De La Recherche Medicale (INSERM)) (20240404)
Anurup Ganguli of San Diego CA (US)
- Number of Gene Editing patents: 4
- Top companies:
- VedaBio, Inc.: 4 patents
- Recent patents:
- 20240254463. ENGINEERED STABLE NUCLEIC ACID-GUIDED NUCLEASES (VedaBio, Inc.) (20240801)
- 20240344044. DELIVERY OF THERAPEUTICS IN VIVO VIA A CRISPR-BASED CASCADE SYSTEM (VedaBio, Inc.) (20241017)
- 20240110164. DELIVERY OF THERAPEUTICS IN VIVO VIA A CRISPR-BASED CASCADE SYSTEM (VedaBio, Inc.) (20240404)
Addison WRIGHT of El Cerrito CA (US)
- Number of Gene Editing patents: 4
- Top companies:
- Scribe Therapeutics Inc.: 4 patents
- Recent patents:
Manuel MOHR of Berkeley CA (US)
- Number of Gene Editing patents: 4
- Top companies:
- Scribe Therapeutics Inc.: 4 patents
- Recent patents:
Noah Michael Jakimo of Cambridge MA (US)
- Number of Gene Editing patents: 4
- Top companies:
- Arbor Biotechnologies, Inc.: 4 patents
- Recent patents:
- 20240301371. CRISPR-ASSOCIATED TRANSPOSON SYSTEMS AND METHODS OF USING SAME (Arbor Biotechnologies, Inc.) (20240912)
- 20240301445. CRISPR-ASSOCIATED TRANSPOSON SYSTEMS AND METHODS OF USING SAME (Arbor Biotechnologies, Inc.) (20240912)
- 20240261435. GENE EDITING SYSTEMS COMPRISING AN RNA GUIDE TARGETING TRANSTHYRETIN (TTR) AND USES THEREOF (Arbor Biotechnologies, Inc.) (20240808)
Kevin Flanigan of Columbus OH (US)
- Number of Gene Editing patents: 4
- Top companies:
- Recent patents:
- 20240261434. PRODUCTS AND METHODS FOR TREATING MUSCULAR DYSTROPHY (RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL) (20240808)
- 20240200066. PRODUCTS AND METHODS FOR TREATING MUSCULAR DYSTROPHY (RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL) (20240620)
- 20240189453. MATERIALS AND METHODS FOR NEUROFIBROMIN 2/MERLIN (NF2) GENE THERAPY (RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL) (20240613)
Manu Tamminen
- Number of Gene Editing patents: 4
- Top companies:
- Genomill Health Oy: 3 patents
- EAWAG, SWISS FEDERAL INSTITUTE OF AQUATIC SCIENCE AND TECHNOLOGY: 1 patents
- Recent patents:
- 20240158843. ACCURATE AND MASSIVELY PARALLEL QUANTIFICATION OF NUCLEIC ACID (EAWAG, SWISS FEDERAL INSTITUTE OF AQUATIC SCIENCE AND TECHNOLOGY) (20240516)
- 20240068010. HIGHLY SENSITIVE METHODS FOR ACCURATE PARALLEL QUANTIFICATION OF VARIANT NUCLEIC ACIDS (Genomill Health Oy) (20240229)
- 20240068022. METHODS FOR ACCURATE PARALLEL DETECTION AND QUANTIFICATION OF NUCLEIC ACIDS (Genomill Health Oy) (20240229)
Maroof ADIL of Davis CA (US)
- Number of Gene Editing patents: 4
- Top companies:
- Scribe Therapeutics Inc.: 4 patents
- Recent patents:
Kamel KHALILI of Bala Cynwyd PA (US)
- Number of Gene Editing patents: 4
- Top companies:
- Recent patents:
- 20240271128. RNA GUIDED ERADICATION OF HERPES SIMPLEX TYPE I AND OTHER RELATED HUMAN HERPESVIRUSES (Temple University - of the Commonwealth System of Higher Education) (20240815)
- 20240336939. CRISPR INDUCED DISRUPTION OF MOGS GENE (TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION) (20241010)
- 20240139294. METHODS AND COMPOSITIONS FOR RNA-GUIDED TREATMENT OF HIV INFECTION (Temple University - of the Commonwealth System of Higher Education) (20240502)
Christian Hinderer of Baltimore MD (US)
- Number of Gene Editing patents: 4
- Top companies:
- Recent patents:
- 20240307511. AAV9-MEDIATED GENE THERAPY FOR TREATING MUCOPOLYSACCHARIDOSIS TYPE I (The Trustees of the University of Pennsylvania) (20240919)
- 20240016903. GENE THERAPY FOR TREATING MUCOPOLYSACCHARIDOSIS TYPE II (The Trustees of the University of Pennsylvania) (20240118)
- 20240024510. GENE THERAPY FOR TREATING MUCOPOLYSACCHARIDOSIS TYPE I (The Trustees of the University of Pennsylvania) (20240125)
Guangping Gao of Worcester MA (US)
- Number of Gene Editing patents: 4
- Top companies:
- University of Massachusetts: 4 patents
- Recent patents:
- 20240076692. MINIGENE THERAPY (University of Massachusetts) (20240307)
- 20240207370. GENE THERAPY FOR BCAA MODULATION IN MAPLE SYRUP URINE DISEASE (MSUD) (University of Massachusetts) (20240627)
- 20240243975. USE OF INVERTED TERMINAL REPEATS (ITRS) FROM ADENO-ASSOCIATED VIRUS SEROTYPES 8 AND RH.39 IN GENE THERAPY VECTORS (University of Massachusetts) (20240718)
Christopher BROWN of Albany CA (US)
- Number of Gene Editing patents: 4
- Top companies:
- Metagenomi, Inc.: 4 patents
- Recent patents:
Angus SIDORE of Oakland CA (US)
- Number of Gene Editing patents: 4
- Top companies:
- Scribe Therapeutics Inc.: 4 patents
- Recent patents:
Suraj MAKHIJA of San Francisco CA (US)
- Number of Gene Editing patents: 4
- Top companies:
- Scribe Therapeutics Inc.: 4 patents
- Recent patents:
Bernd ZETSCHE of Cambridge MA (US)
- Number of Gene Editing patents: 4
- Top companies:
- Beam Therapeutics Inc.: 3 patents
- The Broad Institute, Inc.: 1 patents
- Recent patents:
Alim Ladha of Cambridge MA (US)
- Number of Gene Editing patents: 4
- Top companies:
- ReNAgade Therapeutics Management Inc.: 2 patents
- The Broad Institute, Inc.: 1 patents
- THE BROAD INSTITUTE, INC.: 1 patents
- Recent patents:
- 20240141382. GENE EDITING COMPONENTS, SYSTEMS, AND METHODS OF USE (ReNAgade Therapeutics Management Inc.) (20240502)
- 20240084274. GENE EDITING COMPONENTS, SYSTEMS, AND METHODS OF USE (ReNAgade Therapeutics Management Inc.) (20240314)
- 20240043828. T-DNA MEDIATED GENETIC MODIFICATION (THE BROAD INSTITUTE, INC.) (20240208)
Kendra CONGDON of Durham NC (US)
- Number of Gene Editing patents: 4
- Top companies:
- Tune Therapeutics, Inc.: 4 patents
- Recent patents:
- 20240052328. COMPOSITIONS, SYSTEMS, AND METHODS FOR REDUCING LOW-DENSITY LIPOPROTEIN THROUGH TARGETED GENE REPRESSION (Tune Therapeutics, Inc.) (20240215)
- 20240067968. COMPOSITIONS, SYSTEMS, AND METHODS FOR REGULATION OF HEPATITIS B VIRUS THROUGH TARGETED GENE REPRESSION (Tune Therapeutics, Inc.) (20240229)
- 20240067969. COMPOSITIONS, SYSTEMS, AND METHODS FOR REGULATION OF HEPATITIS B VIRUS THROUGH TARGETED GENE REPRESSION (Tune Therapeutics, Inc.) (20240229)
Top Collaborations in Gene Editing
Top US States for Gene Editing Inventors
Top Cities for Gene Editing Inventors
- Cambridge: 303 inventors
- San Diego: 78 inventors
- Boston: 65 inventors
- San Francisco: 64 inventors
- New York: 56 inventors
- Seattle: 53 inventors
- Zwijnaarde: 49 inventors
- Durham: 46 inventors
- Seoul: 46 inventors
- Shanghai: 39 inventors
- London: 38 inventors
- Wuhan: 38 inventors
- Oakland: 35 inventors
- Berkeley: 33 inventors
- Worcester: 32 inventors
- Daejeon: 31 inventors
- Beijing: 28 inventors
- Wuxi: 28 inventors
- Shenzhen: 27 inventors
- Philadelphia: 27 inventors
